RELIEVE encompasses basic development and proof-of-concept validation of 3 distinct diagnostic and therapeutic tools for people with epilepsy:
-The first device (Nevoa-1) is aiming at predicting seizures at least 30 seconds before happening to alert the patients and caregivers, incorporating an AI-powered real-time brain monitoring unit capable of predicting brain-related anomalies, such as seizures, before they occur. To achieve this, our AI unit monitors brain activity using a patch that records EEG (electroencephalogram) data along with other essential physiological measures.
-The second device (Nevoa-2) aims at pairing ambulatory seizure medication with the prediction device to potentially stop or reduce the severity of seizures.
-The third device (Nevoa-3) is a closed-loop combination of the prediction device with a non-invasive vagus nerve neurostimulation module. The goal of this device is to stop the seizures through neurostimulation before they have a clinical manifestation. Once the AI unit identifies an impending anomaly, the neurostimulation module is activated, stimulating the vagus nerve in a non-invasive manner.
